Overview
I am a cardiologist with a clinical and research interest in heart failure. I take care of patients with various types of heart failure, including patients who are best treated with medications and patients who receive advanced therapies like heart transplantation and mechanical assist devices. I became a heart failure cardiologist to help patients manage their heart conditions and best achieve their goals for their health. I am strongly committed to helping patients thoroughly understand their medical conditions and helping them make informed medical decisions aligned with their preferences.
My research interests are focused on strategies and therapies to improve outcomes and quality of life for patients with heart failure. This involves research through clinical trials and through examining data from real-world clinical practice. Below, you will find my specific research interests:
- Use and dosing of evidence-based heart failure medications
- Management of worsening heart failure outside the hospital
- Novel pharmacological and non-pharmacological approaches to heart failure
- Improving outcomes following a hospitalization for heart failure
- Surrogate and nonfatal endpoints in heart failure clinical trials
- Clinical trial design and operations
- Improving site-based heart failure research
Current Appointments & Affiliations
Associate Professor of Medicine
·
2024 - Present
Medicine, Cardiology,
Medicine
Member in the Duke Clinical Research Institute
·
2020 - Present
Duke Clinical Research Institute,
Institutes and Centers
Recent Publications
Advancement of the implementation of evidence-based therapies for cardiovascular-kidney-metabolic conditions: A multi-stakeholder perspective.
Journal Article Am Heart J · August 2025 Cardiovascular disease remains the leading cause of mortality and healthcare expenditures in the United States. It is also a major contributor to premature mortality, years lived with disability, and rising healthcare costs around the world. Despite the av ... Full text Link to item CiteSite-Level Variation and Factors Associated With an Outpatient Intravenous Diuretic Strategy for Worsening Heart Failure.
Journal Article Am J Cardiol · July 15, 2025 Full text Link to item CiteMyeloperoxidase inhibition in the landscape of anti-inflammatory therapies for heart failure with preserved ejection fraction: the ENDEAVOR trial.
Journal Article Heart Fail Rev · July 2025 Systemic inflammation is considered one of the key physiological drivers in heart failure with preserved ejection fraction (HFpEF) and is associated with worse outcomes. While inflammation has been investigated as a potential therapeutic target in HFpEF, p ... Full text Link to item CiteRecent Grants
Otsuka HF Ph2 POC
Clinical TrialPrincipal Investigator · Awarded by Otsuka Pharmaceutical Development & Commercialization, Inc. · 2024 - 2027PARACOR-19
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2021 - 2026Identifying barriers to and optiMizing in-hosPitaL usE of evidenced-based Medical thErapies for patieNTs with Cardio-Renal-Metabolic Disease (IMPLEMENT-CRM)
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2023 - 2026View All Grants
Education, Training & Certifications
Northwestern University, Feinberg School of Medicine ·
2012
M.D.